Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
Search
Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy
dose adjustments reduce the frequency and intensity of adverse
Positive results reported in HER2 mutated lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Experience our culture during your interview process
Discover if our company is the right fit for you.
Ridgefield, Connecticut, home to our U.S. headquarters, is ranked #1 safest place to live
Read about what makes Ridgefield, Connecticut a great place to live, work, and make a difference in the lives of people and animals.
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US
FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
Real-world data announced for adults with type 2 diabetes
Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult
Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative
Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.
Results from Phase II MASH trial announced at EASL 2024
Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024
BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.
How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US
Click here to learn more about steps that pet owners can take to help prevent Lyme Disease in dogs.
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner
Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program
Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program